HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Soumya Raychaudhuri Selected Research

COVID-19

1/2021IFN-γ and TNF-α drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 lungs and inflammatory diseases with tissue inflammation.
8/2020IFN- γ and TNF- α drive a CXCL10 + CCL2 + macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Soumya Raychaudhuri Research Topics

Disease

38Rheumatoid Arthritis
04/2022 - 10/2008
11Autoimmune Diseases (Autoimmune Disease)
01/2022 - 05/2009
7Macular Degeneration (Age-Related Maculopathy)
01/2016 - 04/2010
5Neoplasms (Cancer)
01/2022 - 01/2003
5Type 1 Diabetes Mellitus (Autoimmune Diabetes)
10/2018 - 01/2013
4Lupus Nephritis
01/2022 - 01/2019
4Inflammation (Inflammations)
01/2022 - 01/2017
4Arthritis (Polyarthritis)
01/2020 - 08/2009
4Schizophrenia (Dementia Praecox)
10/2019 - 11/2014
4Genetic Risk Score
10/2015 - 01/2011
3Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
11/2021 - 01/2016
3Hypersensitivity (Allergy)
10/2020 - 11/2014
3Crohn Disease (Crohn's Disease)
10/2019 - 01/2011
3Osteoarthritis
01/2019 - 01/2016
3Type 2 Diabetes Mellitus (MODY)
02/2013 - 01/2011
2Psoriatic Arthritis
01/2022 - 01/2016
2Systemic Lupus Erythematosus (Libman-Sacks Disease)
01/2022 - 10/2018
2COVID-19
01/2021 - 08/2020
2Disease Susceptibility (Diathesis)
01/2021 - 04/2015
2Ulcerative Colitis
01/2021 - 06/2011
2Genetic Predisposition to Disease (Genetic Predisposition)
01/2019 - 08/2016
2Juvenile Arthritis (Juvenile Idiopathic Arthritis)
01/2018 - 12/2015
2Rheumatic Diseases (Rheumatism)
01/2017 - 09/2015
2Celiac Disease (Celiac Sprue)
06/2015 - 09/2014
2Insulin Resistance
09/2012 - 01/2012
1Psoriasis (Pustulosis Palmaris et Plantaris)
01/2022
1Dermatomyositis (Dermatopolymyositis)
01/2022
1Nephritis
01/2022
1Glioblastoma (Glioblastoma Multiforme)
01/2022
1Ulcer
11/2021
1Communicable Diseases (Infectious Diseases)
01/2021
1Tuberculosis (Tuberculoses)
01/2021
1Drug Hypersensitivity (Drug Allergy)
10/2020
1Prostatic Neoplasms (Prostate Cancer)
01/2020
1Herpes Zoster
01/2019
1Ankylosing Spondylitis
11/2018
1Cardiovascular Diseases (Cardiovascular Disease)
01/2017
1Coronary Artery Disease (Coronary Atherosclerosis)
01/2016
1Knee Osteoarthritis
01/2016
1Immune System Diseases (Immune Disorders)
01/2016
1Acquired Immunodeficiency Syndrome (AIDS)
01/2016
1Bipolar Disorder (Manic Depressive Psychosis)
01/2016

Drug/Important Bio-Agent (IBA)

14Proteins (Proteins, Gene)FDA Link
01/2020 - 09/2003
10Amino AcidsFDA Link
01/2022 - 01/2012
9HLA Antigens (Human Leukocyte Antigens)IBA
01/2022 - 12/2012
9HLA-DRB1 Chains (HLA DRB1)IBA
01/2022 - 01/2012
7Pharmaceutical PreparationsIBA
01/2022 - 05/2013
6Biomarkers (Surrogate Marker)IBA
01/2022 - 07/2015
5CytokinesIBA
01/2022 - 08/2020
5Biological ProductsIBA
01/2022 - 01/2013
5RNA (Ribonucleic Acid)IBA
01/2021 - 01/2019
5HLA-B Antigens (HLA-B)IBA
10/2020 - 01/2012
4Peptides (Polypeptides)IBA
11/2017 - 01/2012
4Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2017 - 07/2010
4AutoantibodiesIBA
04/2014 - 10/2008
3AntigensIBA
01/2022 - 01/2015
3Tumor Necrosis Factor InhibitorsIBA
01/2020 - 04/2015
3Transcription Factors (Transcription Factor)IBA
01/2020 - 05/2013
3Complement Factor H (Factor H)IBA
01/2016 - 10/2011
3HLA-DPB1 antigen (HLA DPB1)IBA
01/2015 - 01/2012
2InterferonsIBA
10/2018 - 03/2014
2histone H3 trimethyl Lys4IBA
10/2018 - 02/2013
2HLA-DQB1 antigen (HLA DQB1)IBA
10/2017 - 01/2012
2DNA (Deoxyribonucleic Acid)IBA
10/2015 - 03/2014
2di-n-hexyl sulfosuccinate (DHSS)IBA
07/2015 - 11/2014
2chemotactic factor inactivatorIBA
07/2015 - 11/2013
2AntibodiesIBA
03/2015 - 12/2012
2LDL Lipoproteins (beta Lipoproteins)IBA
06/2014 - 02/2013
2LipidsIBA
09/2012 - 01/2011
2Anti-Citrullinated Protein AntibodiesIBA
01/2011 - 08/2009
1Eosine Yellowish-(YS) (Eosin)IBA
04/2022
1Hematoxylin (Haematoxylon)IBA
04/2022
1EpitopesIBA
01/2022
1adavosertibIBA
01/2022
1Transforming Growth Factors (Transforming Growth Factor)IBA
01/2022
1Interleukin-16 (Interleukin 16)IBA
01/2022
1Chemotactic FactorsIBA
11/2021
1Adenosine Monophosphate (AMP)IBA
01/2021
1Bacterial ToxinsIBA
01/2021
1Membrane Proteins (Integral Membrane Proteins)IBA
01/2021
1chenodeoxycholate sulfate conjugate (CDCS)IBA
01/2021
1Penicillins (Penicillin)FDA Link
10/2020
1Interleukin-6 (Interleukin 6)IBA
10/2020
1Interleukin-17 (Interleukin 17)IBA
10/2020
1Antirheumatic Agents (DMARD)IBA
01/2020
1Immunomodulating AgentsIBA
01/2019
1Small Cytoplasmic RNAIBA
01/2019
1micaIBA
11/2018
1Membrane Glycoproteins (Membrane Glycoprotein)IBA
01/2018
1Messenger RNA (mRNA)IBA
01/2018
1osteoblast cadherinIBA
01/2018
1Methotrexate (Mexate)FDA LinkGeneric
01/2017
1Folic Acid (Vitamin M)FDA LinkGeneric
01/2017
1transcription factor NF-AT c3IBA
01/2016
1Immunoglobulin G (IgG)IBA
01/2016

Therapy/Procedure

9Therapeutics
11/2021 - 07/2010
2Immunotherapy
01/2021 - 01/2016
2Immunomodulation
01/2021 - 08/2020
2Biological Therapy
01/2017 - 03/2013
1Secondary Prevention
01/2017